DNA, Gene Editing, Genetic Disease and In-Vivo

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

DNA

Gene Editing

Genetic Disease

In-Vivo

Moderna partners with Life Edit for mRNA gene editing therapies

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing

Gene Editing Gene In-Vivo Gene Therapy

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

XTalks

DECEMBER 13, 2023

Both gene therapies are approved for individuals 12 years of age and older with sickle cell disease. The CRISPR system is dubbed to be molecular “scissors” that can cut out parts of genes that are abnormal, deactivating or replacing them with new strands of normal DNA. How do Casgevy and Lyfgenia Work?

Gene Therapy

Gene Therapy FDA Approval Gene In-Vivo

Clinical Research Informer

Moderna partners with Life Edit for mRNA gene editing therapies

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

Stay Connected